Charles Grob, MD
Professor of Psychiatry & Biobehavioral Sciences and Pediatrics, David Geffen School of Medicine at UCLA
Director, Division of Child and Adolescent Psychiatry, Harbor-UCLA Medical Center.
Psychiatric research with hallucinogens
Research DescriptionDr. Grob's clinical interests include mood and anxiety disorders, as well as the self-medication hypothesis of substance abuse as it applies to substance abuse. His research has included the first FDA approved Phase 1 study of the physiological and psychological effects of MDMA (3,4-methlyenedioxymethamphetamine), a multi-national, collaborative study of the Amazonian plant hallucinogen decoction, ayahuasca, in Brazil and a pilot investigation of the safety and efficacy of psilocybin in the treatment of anxiety in adult patients with advanced-stage cancer. He is a founding member of the Heffter Research Institute, which is devoted to fostering and funding research on psychedelics.
- BS, 1975, Columbia University, New York, NY
- MD, 1979, State University of New York, Downstate Medical Center, Brooklyn, NY
Recent and/or Significant Publications
- Danforth AL, Struble CM, Yazar-Klosinski B, Grob CS. MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:237-49. doi:10.1016/j.pnpbp.2015.03.011. Epub 2015 Mar 25. PubMed PMID: 25818246.
- Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. J Psychoactive Drugs. 2014 Jan-Mar;46(1):73-7. PubMed PMID: 24830188.
- Anderson BT, Labate BC, Meyer M, Tupper KW, Barbosa PC, Grob CS, Dawson A, McKenna D. Statement on ayahuasca. Int J Drug Policy. 2012 May;23(3):173-5. doi:10.1016/j.drugpo.2012.02.007. Epub 2012 Mar 27. PubMed PMID: 22459485.